The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

BACKGROUND: The 18-gene tumor inflammation signature (TIS) is a clinical research assay that enriches for clinical benefit to immune checkpoint blockade. We evaluated its ability to predict clinical benefit of immunotherapy in cancer patients treated with PD-1 checkpoint inhibitors in routine clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Damotte, Diane, Warren, Sarah, Arrondeau, Jennifer, Boudou-Rouquette, Pascaline, Mansuet-Lupo, Audrey, Biton, Jérôme, Ouakrim, Hanane, Alifano, Marco, Gervais, Claire, Bellesoeur, Audrey, Kramkimel, Nora, Tlemsani, Camille, Burroni, Barbara, Duche, Angéline, Letourneur, Franck, Si, Han, Halpin, Rebecca, Creasy, Todd, Herbst, Ronald, Ren, Xing, Morel, Pascale, Cesano, Alessandra, Goldwasser, François, Leroy, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829827/
https://www.ncbi.nlm.nih.gov/pubmed/31684954
http://dx.doi.org/10.1186/s12967-019-2100-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829827/
https://www.ncbi.nlm.nih.gov/pubmed/31684954
http://dx.doi.org/10.1186/s12967-019-2100-3

Ejemplares similares